Bottom line
Is ARKG a good fund? The bottom line
ARKG is an actively managed health care sector ETF from ARK Invest.
It charges 0.75% — about $75 a year on every $10,000 invested, cheaper than 66% of health care sector funds we track.
It returned −28.1% over one year, −6.5% a year over five years, +1.9% a year over ten (as of Dec 31, 2024, per its prospectus).
With $1.6 billion in net assets and 33 holdings, its largest position is 10x Genomics Inc (9.4%) and the top 10 make up 59.1% of the portfolio.
What to watch
- 5-year return in the bottom quarter of its category
- Concentrated: top 10 holdings are 59.1% of assets
Updated Nov 19, 2026
What ARKG invests in
The ARK Genomic Revolution ETFs (Fund) investment objective is long -term growth of capital.
The Fund is an actively -managed exchange -traded fund (ETF) that will invest under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors, including healthcare, information technology, materials, energy and consumer discretionary, that are relevant to the Funds investment theme of the genomics* revolution (Genomics Revolution Companies), which is described below: Genomic Revolution Companies. Companies that the Adviser believes are substantially focused on and are expected to substantially benefit from extending and enhancing the quality of human and other life by incorporating technological and scientific developments, improvements and advancements in genomics into their business, such as by offering new products or services that rely on genomic sequencing,** analysis, synthesis or instrumentation.…
From the fund's prospectus (filed Nov 26, 2025).
ARKG performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| ARKG | −28.1% | −6.5% | +1.9% |
| Health Care Sector median | +14.5% | +4.2% | +7.9% |
Source: Fund prospectus, as of Dec 31, 2024
What ARKG costs
On a $10,000 investment, ARKG's 0.75% expense ratio costs about $75 a year. The prospectus estimates $930 in total costs over 10 years (assuming 5% annual returns). The median health care sector fund charges 0.96%.
ARKG top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | 10x Genomics Inc TXG | 9.39% |
| 2 | Twist Bioscience Corp TWST | 7.73% |
| 3 | Tempus Ai Inc TEM | 6.56% |
| 4 | Crispr Therapeutics Ag CRSP | 6.29% |
| 5 | Personalis Inc PSNL | 5.47% |
| 6 | Absci Corp ABSI | 5.14% |
| 7 | Guardant Health Inc GH | 4.74% |
| 8 | Illumina Inc ILMN | 4.74% |
| 9 | Eli Lilly & Company LLY | 4.68% |
| 10 | Caredx Inc CDNA | 4.30% |
Source: SEC Form N-PORT, period ended Jul 31, 2026
The top 10 make up 59.1% of the fund. See all top 25 holdings and asset mix →